VECT
Closed
Vectivbio Holding Ag
16.85
0.00 (0.00%)
Last Update: 17 Jul 2023 16:30:00
Yesterday: 16.85
Day's Range: 16.85 - 16.85
Send
sign up or login to leave a comment!
When Written:
8.75
VectivBio Holding AG is a clinical-stage biopharmaceutical company that focuses on developing and commercializing innovative treatments for serious rare diseases. The company was founded in 2019 and is headquartered in Basel, Switzerland.
VectivBio's pipeline includes several product candidates for rare diseases, such as Cushing's disease, polycystic kidney disease, and focal segmental glomerulosclerosis. Its lead product candidate, apraglutide, is a potential treatment for short bowel syndrome and is currently in Phase 3 clinical trials.
The company's approach to drug development involves identifying and acquiring promising early-stage drug candidates, and then leveraging its expertise in clinical development and regulatory affairs to advance them through clinical trials and regulatory approval.
VectivBio is backed by a group of leading life sciences investors, including Novo Holdings, OrbiMed, and RA Capital Management.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
VectivBio's pipeline includes several product candidates for rare diseases, such as Cushing's disease, polycystic kidney disease, and focal segmental glomerulosclerosis. Its lead product candidate, apraglutide, is a potential treatment for short bowel syndrome and is currently in Phase 3 clinical trials.
The company's approach to drug development involves identifying and acquiring promising early-stage drug candidates, and then leveraging its expertise in clinical development and regulatory affairs to advance them through clinical trials and regulatory approval.
VectivBio is backed by a group of leading life sciences investors, including Novo Holdings, OrbiMed, and RA Capital Management.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!